Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for BeOne Medicines (BEIGF) over the last 10 years, with Q3 2025 value amounting to 0.02%.

  • BeOne Medicines' Return on Invested Capital rose 2400.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 2400.0%. This contributed to the annual value of 0.18% for FY2024, which is 1100.0% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Return on Invested Capital is 0.02%, which was up 2400.0% from 0.06% recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Return on Invested Capital peaked at 0.02% during Q3 2025, and registered a low of 0.38% during Q1 2023.
  • For the 5-year period, BeOne Medicines' Return on Invested Capital averaged around 0.24%, with its median value being 0.23% (2024).
  • As far as peak fluctuations go, BeOne Medicines' Return on Invested Capital soared by 3300bps in 2021, and later tumbled by -2400bps in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' Return on Invested Capital stood at 0.13% in 2021, then plummeted by -189bps to 0.37% in 2022, then increased by 17bps to 0.31% in 2023, then soared by 43bps to 0.18% in 2024, then surged by 109bps to 0.02% in 2025.
  • Its last three reported values are 0.02% in Q3 2025, 0.06% for Q2 2025, and 0.11% during Q1 2025.